TREX WIND-DOWN, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-12-10: Form 8-K; Period of report 2019-12-10; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2019-09-20: Form 8-K; Period of report 2019-09-20; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2019-09-09: Form 8-K; Period of report 2019-09-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2019-07-17: Form 8-K; Period of report 2019-07-17; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-12-10 | 8-K | 2019-12-10 | 2.02 Results of Operations and Financial Condition | 2.02 On December 10, 2019, BioPharmX Corporation (the “Company”) issued a press release announcing its financial results and certain other information for the quarter ended October 31, 2019. | bpmx-20191210x8k.htm |
| 2019-09-20 | 8-K | 2019-09-20 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On September 19, 2019, BioPharmX Corporation (“Company”) received notification (the “Extension Letter”) from NYSE American LLC (“NYSE American”) that provided an extension from September 24, 2019 until March 24, 2020 (the term of the extension, the “Plan Period”) to regain compliance with certain NYSE American continued listing standards (the “Listing Standards”). | bpmx-20190920x8k.htm |
| 2019-09-09 | 8-K | 2019-09-09 | 2.02 Results of Operations and Financial Condition | 2.02 On September 9, 2019, BioPharmX Corporation (the “Company”) issued a press release announcing its financial results and certain other information for the quarter ended July 31, 2019. | bpmx-20190909x8k.htm |
| 2019-07-17 | 8-K | 2019-07-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 16, 2019, BioPharmX Corporation (the “Company”) announced the appointment of Steven M. Bosacki, to serve as its Chief Operating Officer, effective as of July 16, 2019. | bpmx-20190717x8k.htm |
| 2019-07-11 | 8-K | 2019-07-11 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 BioPharmX Corporation (the “Company”) held its Annual Meeting of Stockholders on July 10, 2019 (the “Annual Meeting”). | bpmx-20190711x8k.htm |
| 2019-06-25 | 8-K | 2019-06-25 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On June 25, 2019, BioPharmX Corporation (the “Company”) issued a press release announcing the topline results from the Company’s Phase 2b clinical trial evaluating its product candidate BPX-04, a novel topical gel formulation of minocycline for the treatment of moderate-to-severe papulopustular rosacea. 8.01 On June 25, 2019, the Company announced that it achieved the primary and secondary endpoints in its Phase 2b clinical trial evaluating BPX-04, a 1% topical minocycline gel product candidate for the treatment of moderate-to-severe papulopustular rosacea. | f8-k.htm |
| 2019-06-11 | 8-K | 2019-06-11 | 2.02 Results of Operations and Financial Condition | 2.02 On June 11, 2019, BioPharmX Corporation (the “Company”) issued a press release announcing its financial results and certain other information for the quarter ended April 30, 2019. | bpmx-20190611x8k.htm |
| 2019-05-16 | 8-K | 2019-05-16 | 1.01 Entry into a Material Definitive Agreement | 1.01 On May 16, 2019, BioPharmX Corporation (the “Company”) entered into a Capital on DemandTM Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC, as agent (“JonesTrading”), pursuant to which the Company may offer and sell, from time to time through JonesTrading, shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $8.5 million (the “Shares”). | a19-10082_18k.htm |
| 2019-04-26 | 8-K | 2019-04-26 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On April 25, 2019, BioPharmX Corporation (the “Company”) filed a Certificate of Amendment to its Certificate of Incorporation to effect a reverse stock split (the “Reverse Stock Split”) of the Company’s common stock at a ratio of 1-for-25, effective at 4:01 p.m. | bpmx-20190426x8k.htm |
| 2019-03-25 | 8-K | 2019-03-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | bpmx-20190325x8k.htm |
| 2019-03-21 | 8-K | 2019-03-21 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 On March 21, 2019, BioPharmX Corporation (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company will sell to the Purchasers an aggregate of 43,645,000 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”) at a price of $0.09 per share in a registered direct offering (the “Offering”). 7.01 On March 21, 2019, the Company issued a press release regarding the transactions described above under Item 1.01 of this Current Report on Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | a19-6993_18k.htm |
| 2019-03-14 | 8-K | 2019-03-14 | 2.02 Results of Operations and Financial Condition | 2.02 On March 14, 2019, BioPharmX Corporation (the “Company”) issued a press release announcing its financial results and certain other information for the quarter and fiscal year ended January 31, 2019. | bpmx-20190314x8k.htm |
| 2019-02-27 | 8-K | 2019-02-27 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On February 25, 2019, BioPharmX Corporation (the “Company”) received notification (the “Extension Letter”) from the NYSE American LLC (“NYSE American”) that provided an extension from February 27, 2019 until April 30, 2019 (the term of the extension, the “Plan Period”) to regain compliance with certain NYSE American continued listing standards (the “Listing Standards”). | bpmx-20190227x8k.htm |
| 2019-02-04 | 8-K | 2019-02-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 30, 2019, the Board of Directors (the “Board”) of BioPharmX Corporation (the “Company”) authorized an increase in the number of members of the Board from four to five. | bpmx-20190204x8k.htm |